---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-040497"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T06:59:27.728351+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Supernus acquires NV-5138/SPN-820 assets from Navitor; up to $350M in milestones

## Summary
- Supernus buys all IP, inventory, and regulatory materials for CNS compound NV-5138 (SPN-820).
- Consideration: complete a Phase 2b study plus milestone payments up to $350M tied to development, regulatory, and commercial goals.
- No upfront cash; Supernus may stop pursuing milestones if Phase 2b study fails in its sole discretion.
- Agreement includes five-year post-closing non-compete and non-solicitation covenants for Navitor parties.

## SEC filing metadata
- accession: 0001104659-26-040497
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000110465926040497/0001104659-26-040497-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000110465926040497/tm2611273d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-040497
- JSON: https://secwatch.observer/filing/0001104659-26-040497.json
- Plain text: https://secwatch.observer/filing/0001104659-26-040497.txt

## Source-grounded claims
- claim_id: b18d0ba85cae3e7580bed5326281cd703aecf5dd
  claim: SUPERNUS PHARMACEUTICALS, INC. entered into Asset Purchase Agreement with Navitor Pharmaceuticals, Inc., Navitor Pharmaceuticals, LLC valued at up to $350 million (effective 2026-04-01).
  evidence_excerpt: On April 1, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Agreement”), together with related ancillary transaction documents, with Navitor Pharmaceuticals, Inc., a Delaware corporation (“Navitor”), Navitor Pharmaceuticals, LLC, a Delaware limited liability company (“Navitor Parent,” and, together with Navitor, the “Sellers”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000110465926040497/0001104659-26-040497-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.